Standard care

Preclinical

MMuhammad Aamir Latif

Standard care is one of 2 therapeutic programs targeting Chronic Sinusitis. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[2][1]

Indication

Chronic SinusitisNot yet recruiting

Chronic SinusitisPreclinical

Not yet recruiting

Competition

Competitive Landscape

1 competitor in Chronic Sinusitis

#DrugCompanyPhaseTrials

Bee Venom Phonophoresis

SSinai University

Preclinical

1 2

Standard care

MMuhammad Aamir Latif

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2027

PreclinicalNot yet recruiting

Chronic Sinusitis

NCT07151313

Q3 2029

Phase 3Recruiting

Burn Injury

NCT07212998

Clinical

Trials by Indication[1]

Congenital Adrenal Hyperplasia1 trial

An Open-label, Randomized, Titration-blinded, Phase III Study of Efficacy, Safety and Tolerability Of Chronocort® Compared With Standard Glucocorticoid REeplacement Therapy in the Treatment of Participants Aged 16 Years and Over With Congenital Adrenal Hyperplasia

Withdrawn·NNeurocrine UK Limited·Phase 3·NCT03532022

Burn Injury1 trial

Plasma Resuscitation Early for Evaluating Volume and Endotheliopathy of Thermal Injury (PREEVEnT) Trial

Recruiting·JJason Sperry·Phase 3·NCT07212998·750 enrolled

Chronic Obstructive Pulmonary Disease1 trial

Beta-blockeRs tO patieNts With CHronIc Obstructive puLmonary diseasE

Completed·OOle Frobert, MD, PhD·Approved·NCT03566667·1,713 enrolled

Chronic Sinusitis1 trial

Efficacy of Bee Venom Phonophoresis in Treating Chronic Sinusitis: A Double-Blind Randomized Controlled Trial

Not yet recruiting·SSinai University·Preclinical·NCT07151313·30 enrolled

Septic Shock1 trial

Outcome of Using Hydrocortisone in Early Treatment of Pediatric Septic Shock

Completed·MMuhammad Aamir Latif·Preclinical·NCT07313670·122 enrolled

Sources

References

[1]
ClinicalTrials.gov — 5 trial records for Standard care. U.S. National Library of Medicine, National Institutes of Health.
[2]
Open Targets Platform — Drug–disease associations for Standard care. EMBL-EBI & Wellcome Sanger Institute.
[3]
SEC EDGAR — Muhammad Aamir Latif company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Highest Phase: Preclinical[1]
Company: MMuhammad Aamir Latif

Standard care

Status by Indication[2][1]

Competitive Landscape

Expected Milestones

Q4 2027

Q3 2029

Trials by Indication[1]

Congenital Adrenal Hyperplasia1 trial

Burn Injury1 trial

Chronic Obstructive Pulmonary Disease1 trial

Chronic Sinusitis1 trial

Septic Shock1 trial

References

Drug Info

Quick Facts

Related News